Wolverine Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wolverine Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$17K	–	2169
2021 Q4	$17K	Hold	200	–	–	﹤0.01%	1755
2021 Q3	$15K	Hold	200	–	–	﹤0.01%	1698
2021 Q2	$16K	Hold	200	–	–	﹤0.01%	1949
2021 Q1	$15K	Buy	+200	New	+$16.3K	﹤0.01%	1803
2019 Q1	–	Sell	-900	Closed	-$76K	–	1392
2018 Q4	$76K	Hold	900	–	–	﹤0.01%	1385
2018 Q3	$87K	Sell	900 -600	-40%	-$59.9K	﹤0.01%	1301
2018 Q2	$141K	Buy	+1,500	New	+$131K	﹤0.01%	1144
2017 Q1	–	Sell	-12,500	Closed	-$1.03M	–	1185
2016 Q4	$1.03M	Sell	12,500 -40,000	-76%	-$3.44M	0.01%	527
2016 Q3	$4.86M	Buy	52,500 +40,000	+320%	+$3.77M	0.07%	252
2016 Q2	$972K	Buy	12,500 +12,375	+9,900%	+$1.05M	0.01%	583
2016 Q1	$18K	Hold	125	–	–	﹤0.01%	1002
2015 Q4	$113K	Hold	125	–	–	﹤0.01%	980
2015 Q3	$169K	Hold	125	–	–	﹤0.01%	959
2015 Q2	$354K	Buy	125 +50	+67%	+$6.2K	0.01%	747
2015 Q1	$172K	Buy	+75	New	+$7.95K	﹤0.01%	900
2014 Q4	–	Sell	-4	Closed	-$5K	–	2202
2014 Q3	$5K	Buy	+4	New	+$263	﹤0.01%	2127
2013 Q4	–	Sell	-177	Closed	-$5K	–	2703
2013 Q3	$5K	Buy	+177	New	+$11.8K	﹤0.01%	2374

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wolverine Asset Management's BMRN Position: Q1 2023 in Review

Wolverine Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 61 shares — an estimated $6.31K sold.

Wolverine Asset Management first reported a position in BMRN in Q2 2014 and held it in 17 quarters. The position peaked at $1.49M in Q1 2021. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Wolverine Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Wolverine Asset Management sold 61 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $6.31K.
Wolverine Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 17 quarters.
Wolverine Asset Management's BioMarin Pharmaceuticals position peaked at $1.49M in Q1 2021.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.